Chondroprotectives used for the treatment of knee osteoarthritis: A comment

Bone Marrow Mesenchymal Stem Cells Exert Anti-Inflammatory and Chondrocyte Activity in Rats with Knee Arthritis

This study investigates whether bone marrow mesenchymal stem cells (BMSCS) exert antiinflammatory and chondrocyte activity in rats with knee arthritis. 36 SD rats were randomly divided into Health group (H group), knee arthritis group (K group), methotrexate group (M group), BMSCs group (B Group), with 9 rats in each group followed by analysis of the levels of TNF-α, IL-6 and IL-1, morphology of knee cartilage by H&E staining, chondrocyte activity by MTT assay, and the expression of NO, ERα and cGMP by Western Blot. H&E staining showed that the surface of knee cartilage in group H was smooth and the morphology of chondrocytes was normal. In group K, bone fissure was formed on articular cartilage surface, and the hyperplasia of deep cells was disorder. The surface of articular cartilage in group B and GROUP M gradually became smooth. Compared with group H, the levels of TNF-α, IL-6 and IL-1 were increased and chondrocytes activity was decreased in group K (P < 0.05) with decreased TNF-α, IL-6 and IL-1 levels and increased chondrocytes activity in group M and B (P < 0.05). The levels of NO, ERα and cGMP in knee cartilage of group K were decreased (P < 0.05) and increased in group M and group B (P < 0.05). Bone marrow mesenchymal cells can down-regulate the levels of IL-6, IL-1 and TNF-α, enhance the activity of chondrocytes, and up-regulate the levels of NO, ERα and cGMP, thus providing a new idea for the treatment of knee arthritis.

A bond between rheumatic diseases and cancer in the elderly: The interleukin-6 pathway

Interleukin (IL)-6 is a soluble factor secreted by T lymphocytes, involved in antibody generation by B lymphocytes. The IL-6 pathway has risen as a pivotal pathway implicated in immune regulation and dysregulation in various rheumatic diseases. Nonetheless, elevated IL-6 levels can also play a role in cancer. Targeting the IL-6 pathway has led to innovative therapeutic approaches for rheumatic diseases and for COVID-19, particularly in the elderly. Indeed, tocilizumab, an agent targeting IL-6, has recently amassed significant attention as a promising univocal agent for different conditions. In this viewpoint, we sought to recall and describe the common pathway among osteoarthritis, rheumatoid arthritis, and cancer, suggesting that anti-IL-6 may be considered a jack-of-all-trades against inflammaging in the elderly.